New approach to heart failure: Integrated traditional Chinese with Western medicine

Abstract

Heart failure (HF) is a major global healthcare problem leading to substantial deterioration of prognosis. The current clinical guidelines in HF have begun to emphasize the importance of traditional Chinese medicine (TCM). TCM has been utilized in clinical practice for over 2000 years and is capable of treating a variety of HF pathogenic issues. This review summarizes the classification, pathophysiology, and treatment of HF from three perspectives: Western medicine, TCM, and integrated traditional Chinese and Western medicine (ITCWM). Emphasizing the most recent evidence, this review consolidates knowledge on ITCWM treatments for HF pertaining to different TCM syndromes, including TCM decoctions, oral patent Chinese medicine, TCM injections, as well as therapies like acupuncture and moxibustion. Additionally, this review explores TCM approaches to HF prevention, such as tai chi, Baduanjin exercise, and Sanfu acupoint herbal patching. The findings of this study suggest that ITCWM holds promise for the treatment and rehabilitation of HF. However, further research is warranted to elucidate the underlying mechanisms.

Keywords

heart failure / integrative medicine / randomized controlled trials / traditional Chinese medicine

References

[1] Heidenreich PA , Bozkurt B , Aguilar D , et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145 (18): e10.

[2] James SL , Abate D , Abate KH , et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392 (10159): 1789- 1858.

[3] Bueno H , Moura B , Lancellotti P , Bauersachs J . The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. Eur Heart J. 2021; 42 (6): 657- 670.

[4] Wang H , Chai K , Du M , et al. Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis. Circ Heart Fail. 2021; 14 (10): e008406.

[5] McDonagh TA , Metra M , Adamo M , et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022; 24 (1): 4- 131.

[6] Zhang Y , Zhang J , Butler J , et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China Heart Failure (China-HF) Registry. J Card Fail. 2017; 23 (12): 868- 875.

[7] Conrad N , Judge A , Canoy D , et al. Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86,000 individuals. JAMA Cardiol. 2019; 4 (11): 1102- 1111.

[8] Lawson CA , Zaccardi F , Squire I , et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health. 2019; 4 (8): e406- e420.

[9] Virani SS , Alonso A , Aparicio HJ , et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021; 143 (8): e254- e743.

[10] Zhu ZZ , Yuan CY , Yuan ZY , et al. Exploration of the ancient disease name of heart failure. J Basic Chin Med. 2017; 23 (11): 1509- 1511 (in Chinese).

[11] Chen KJ , Wu ZG , Zhu MJ , et al. 2016 Expert consensus on diagnosis and treatment of chronic heart failure with integrated traditional Chinese and Western medicine. Chin J Integrated Tradit West Med. 2016; 36 (2): 133- 141 (in Chinese).

[12] Project Group of Traditional Chinese Medicine Guideline for Diagnosis and Treatment . Traditional Chinese medicine guideline for diagnosis and treatment of chronic heart failure (2022). J Tradit Chin Med. 2023; 64 (7): 743- 756 (in Chinese).

[13] Standardization Project Group of Clinical Application Guidelines for the Treatment of Dominant Diseases with ready-for-use traditional Chinese medicine . Clinical application guidelines of Chinese patent medicines for heart failure (2021). Chin J Integrated Tradit West Med, 2022, 42 (3): 261- 275 (in Chinese).

[14] Mascolo A , Di Mauro G , Cappetta D , et al. Current and future therapeutic perspective in chronic heart failure. Pharmacol Res. 2022; 175: 106035.

[15] Murphy SP , Kakkar R , McCarthy CP , Januzzi JL . Inflammation in heart failure. J Am Coll Cardiol. 2020; 75 (11): 1324- 1340.

[16] Simmonds SJ , Cuijpers I , Heymans S , Jones EAV . Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. Cells. 2020; 9 (1): 242.

[17] Zhou B , Tian R . Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest. 2018; 128 (9): 3716- 3726.

[18] Taqueti VR , Di Carli MF . Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol. 2018; 72 (21): 2625- 2641.

[19] Yu CQ , Li XT , Shi F , et al. Effect of Qili Qiangxin capsule on adenosine content in chronic heart failure rats with insufficiency of heart-qi. Chin J Exp Tradit Med Formulae. 2012; 18 (3): 174- 177 (in Chinese).

[20] Li J , Zhong SJ , Kuang HF , et al. Pathogenesis of metabolic remodeling of energy substrate based on theory of deficient qi stagnation and progress of Chinese medicine intervention. Chin J Exp Tradit Med Formulae. 2023; 29 (17): 195- 202 (in Chinese).

[21] Shen L , Shi RJ , Sun WX , et al. Application of metabolomics in TCM syndromes research of heart failure. Chin J Inf Tradit Chin Med. 2023; 30 (5): 171- 175 (in Chinese).

[22] Zhong SJ , Li XC , Li J , et al. Plasma metabonomics of rats with heart failure with heart-qi yin deficiency syndrome. J Hunan Univ Chin Med. 2018; 38 (9): 981- 985 (in Chinese).

[23] Liu Y , Zhao Y , Yin HL , et al. Preliminary screening of serum metabolites in patients with heart failure with qi deficiency and blood stasis syndrome based on non-targeted metabonomics. Lishizhen Med Materia Medica Res. 2020; 31 (11): 2789- 2792 (in Chinese).

[24] Wang HH , Li M , Zhu YP , et al. Correlation between TCM syndrome types and inflammatory cytokines TNF-α, IL-1, IL-6 in patients with chronic heart failure. N Chin Med. 2015; 47 (1): 33- 35 (in Chinese).

[25] Januzzi JL , Prescott MF , Butler J , et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019; 322 (11): 1085- 1095.

[26] Solomon SD , McMurray JJV , Anand IS , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019; 381 (17): 1609- 1620.

[27] Zannad F , Ferreira JP , Pocock SJ , et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020; 396 (10254): 819- 829.

[28] Armstrong PW , Pieske B , Anstrom KJ , et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020; 382 (20): 1883- 1893.

[29] Armstrong PW , Lam CSP , Anstrom KJ , et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 2020; 324 (15): 1512- 1521.

[30] Mack M , Carroll JD , Thourani V , et al. Transcatheter mitral valve therapy in the United States: a report from the STS-ACC TVT registry. J Am Coll Cardiol. 2021; 78 (23): 2326- 2353.

[31] Wiegn P , Chan R , Jost C , et al. Safety, performance, and efficacy of cardiac contractility modulation delivered by the 2-lead optimizer smart system: the FIX-HF-5C2 study. Circ Heart Fail. 2020; 13 (4): e006512.

[32] Gentile F , Passino C , Emdin M , Giannoni A . Baroreflex activation therapy in heart failure: targeting the right patient. Eur J Heart Fail. 2022; 24 (9): 1674- 1676.

[33] Packer M , Butler J , Zannad F , et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation. 2021; 144 (16): 1284- 1294.

[34] Zhu M , Wei J , Li Y , et al. Efficacy and mechanism of Buyang Huanwu decoction in patients with ischemic heart failure: a randomized, double-blind, placebo-controlled trial combined with proteomic analysis. Front Pharmacol. 2022; 13: 831208.

[35] Dai HX , Xiang YH , Zhai WJ . Clinical observation on treatment of chronic heart failure (qi deficiency and blood stasis sydrome) with Buyang Huanwu decoction. Heilongjiang J Tradit Chin Med. 2021; 50 (2): 52- 53 (in Chinese).

[36] Hu XM , Fang ZX , Hou MY . Clinical observation on treatment of chronic heart failure with Buyang Huanwu decoction. Guangming J Chin Med. 2021; 36 (15): 2551- 2553 (in Chinese).

[37] Mao J , Zhang J , Lam CSP , et al. Qishen Yiqi dripping pills for chronic ischaemic heart failure: results of the CACT-IHF randomized clinical trial. ESC Heart Fail. 2020; 7 (6): 3881- 3890.

[38] Wang S , Zhao ZQ , Qang XL , et al. A multicenter, prospective cohort study of Qishen Yiqi dripping pills in the treatment of ischemic heart failure. J Tradit Chin Med. 2022; 63 (7): 635- 643 (in Chinese).

[39] Wang M , Shan Y , Wu C , et al. Efficacy and safety of Qishen Yiqi dripping pill for heart failure with preserved ejection fraction: a systematic review and meta-analysis. Front Pharmacol. 2021; 11: 626375.

[40] Zhang KX , Geng W , Jiang YM , et al. Effect of Qishenyiqi dropping pill on heart failure with preserved ejection fraction. Clin Focus. 2019; 34 (11): 995- 998 (in Chinese).

[41] Song SY . Effect of Qishen Yiqi dripping pills combined with nicorandil on serum NT-proBNP, hs-CRP, Hcy and CysC in patients with left ventricular ejection fraction retaining heart failure after emergency PCI. Modern J Integrated Tradit Chin Western Med. 2020; 29 (5): 514- 518 (in Chinese).

[42] Hou JW , Yang J . Effect of Qishen Yiqi dripping pills combined with bisoprolol on oxidative stress and cardiac remodeling in diabetic patients with left ventricular ejection fraction retaining heart failure-clinical data of 60 cases. Jiangsu J Tradit Chin Med. 2019; 51 (10): 26- 28 (in Chinese).

[43] Chang WN , Wang X , Chu PP , et al. Clinical efficacy and influence on myocardial fibrosis of high-dose astragalus injection combined with ivabradine in the refractory heart failure patients. J North China Univ Sci Technol. 2022; 24 (5): 388- 392+405 (in Chinese).

[44] Zhang XH . Effect of Huangqi injection on cardiac function and neuroendocrine function in patients with congestive heart failure. Henan Med Res. 2020; 29 (5): 857- 859 (in Chinese).

[45] Gan PZ . Efficacy of astragalus injection in the treatment of chronic heart failure and its effect on BNP and CA125. China Med Pharm. 2019; 9 (9): 48- 51 (in Chinese).

[46] Xian W . Influence of recombinant human BNP combined Astragalus injection on heart function and serum levels of inflammatory factors in AMI patients with post-PCI heart failure. Chin J Cardiovasc Rehabil Med. 2019; 28 (4): 424- 428 (in Chinese).

[47] Li Q , Su L , Zhou R , et al. Efficacy and safety of Yangyin Shuxin decoction—a Chinese herbal medicine formula for heart failure with preserved ejection fraction: a randomized controlled trial. Evid Based Complementary Altern Med. 2022; 2022: 1- 12.

[48] Zhao ZQ , Wang XL , Zhang P , et al. Effect of Yangyin Shuxin decoction on quality of life of patients with heart failure with normal ejection fraction. J Tradit Chin Med. 2018; 59 (21): 1843- 1847 (in Chinese).

[49] Li B , Liu WH , Li XS , et al. Using speckle tracking imaging to evaluate the left ventricular systolic function of heart failure with preserved ejection fraction by treatment of Yangyin Shuxin decoction. Chin J Integrated Tradit West Med. 2020; 40 (9): 1064- 1069 (in Chinese).

[50] Mo XY , Wang XL , Hou YZ , et al. Meta-analysis of randomized controlled trial of Buyi Qiangxin tablets combined with Western medicine in the treatment of chronic heart failure. Tianjin J Tradit Chin Med. 2018; 35 (12): 921- 925 (in Chinese).

[51] Yang XR , Wang ZY , Liu SQ , et al. Effect of Buyi Qiangxin tablets on adverse events in patients with chronic heart failure. N Chin Med. 2019; 51 (2): 104- 106 (in Chinese).

[52] Wu WJ , Gao LL , Sha S , et al. Clinical study of Buyiqiangxin Tablets combined with sacubitril valsartan sodium in treatment of chronic heart failure. Drugs Clin. 2022; 37 (10): 2281- 2286 (in Chinese).

[53] Nie H , Li S , Liu M , et al. Yiqi Fumai injection as an adjuvant therapy in treating chronic heart failure: a meta-analysis of 33 randomized controlled trials. Evid Based Complementary Altern Med. 2020; 2020: 1- 12.

[54] Wei L , Wen M , Tian YH . Clinical study on Yiqi Fumai injection (freezed-dried) combined with bisoprolol in treatment of congestive heart failure. Drugs Clin. 2021; 36 (4): 782- 786 (in Chinese).

[55] Shi D , Xu XY , Zhao TH , et al. Clinical effect of Yiqi Fumai lyophilized injection on coronary heart disease with chronic heart failure. Drug Eval Res. 2022; 45 (11): 2291- 2295 (in Chinese).

[56] Li XX . Clinical trial of Shenmai injection combined with atorvastatin calcium tablets in the treatment of chronic heart failure with coronary heart disease. Chin J Clin Pharmacol. 2018; 34 (3): 221- 223 (in Chinese).

[57] Wang SM , Ye LF , Wang LH . Shenmai injection improves energy metabolism in patients with heart failure: a randomized controlled trial. Front Pharmacol. 2020; 11: 459.

[58] Sun P , Ji WL , Zang JP , et al. Clinical effect of Shenmai injection combined with nicorandil on patients with heart failure. Chin Tradit Pat Med. 2019; 41 (10): 2550- 2552 (in Chinese).

[59] Guan H , Dai GH , Gao WL , et al. Effect of Shenmai injection on long-term prognosis of patients with chronic heart failure: a multicenter, large sample capacity, long-term follow-up retrospective cohort study. Chin J Integr Med. 2022; 28 (4): 312- 318.

[60] Zhou XQ , Zhao PY , Zhang SX , et al. Bayesian meta-analysis on the efficacy of Zhenwu decoction series for cardiac function in patients with chronic heart failure. Chin J Inf Tradit Chin Med. 2023; 30 (7): 37- 44 (in Chinese).

[61] Wang J , Li F , Zhou XL , et al. Clinical observation of modified Zhenwutang in treatment of chronic heart failure patients with yang deficiency syndrome. Chin J Exp Tradit Med Formulae. 2018; 24 (11): 173- 178 (in Chinese).

[62] Li F . Clinical Observation of Zhenwu decoction combined with valsartan in treatment of chronic heart failure complicated with renal insufficiency. Liaoning J Tradit Chin Med. 2020; 47 (4): 98- 101 (in Chinese).

[63] Li X , Zhang J , Huang J , et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013; 62 (12): 1065- 1072.

[64] Bu XP , Zhang LH . Clinical study of Qili Qiangxin capsules on elderly heart failure with ejection fraction retention. Shanxi Med J. 2021; 50 (10): 1677- 1679 (in Chinese).

[65] Dong M , Sun XD , Jia XK , et al. ClinicaI trial of Qiliqiangxin capsule combined with trimetazidine in the treatment of heart failure with preserved left ventricular ejection fraction. Chin J Misdiagn. 2018; 13 (1): 9- 11 (in Chinese).

[66] Zhang J . Clinical effect of Qili Qiangxin capsule combined with Xinhuosu on heart failure with ejection fraction retention. World Latest Med Inf. 2019; 19 (31): 170+175 (in Chinese).

[67] Gao C , Jin LZ , Wen L , et al. Clinical study on Qili Qiangxin capsule in treating chronic heart failure with ejection fraction preservation. Chin J Integr Med Cardio-Cerebrovasc Dis. 2019; 17 (17): 2621- 2623 (in Chinese).

[68] Wang X , Zhao Z , Mao J , et al. Randomized, double-blinded, multicenter, placebo-controlled trial of Shenfu injection for treatment of patients with chronic heart failure during the acute phase of symptom aggravation (yang and qi deficiency syndrome). Evid Based Complementary Altern Med. 2019; 2019: 9297163.

[69] Li M , Zhang Y , Wan Q , et al. Use of levosimendan combined with Shenfu injection to treat acute heart failure patients with hypotension: a prospective randomized controlled single-blind study. BMC Cardiovasc Disord. 2022; 22: 130.

[70] Xue Z . Clinical study on the effect of Shenfu injection on NT-proBNP and quality of life in patients with diastolic heart failure. Guide China Med. 2015; 13 (9): 201- 202 (in Chinese).

[71] Yang P , Li H , Zhang YN , et al. Clinical effect of Shenfu injection on diastolic heart failure. Chin J Gerontol. 2016; 36 (9): 2103- 2105 (in Chinese).

[72] Dai J , Mao W , Liu Q , et al. Study on the clinical curative effect of Shenfu injection on diastolic heart failure. China J Tradit Chin Med Pharm. 2014; 29 (12): 3939- 3941 (in Chinese).

[73] Xue J , Xu Y , Deng Y , et al. The efficacy and safety of Xinmailong injection in patients with chronic heart failure: a multicenter randomized double-blind placebo-controlled trial. J Altern Complementary Med. 2019; 25 (8): 856- 860.

[74] Huang JB , Wang FL , Chen LX , et al. Clinical observation of Xinmailong injection in the treatment of senile diastolic heart failure. Chin J Integ Med Cardio-Cerebrovasc Dis. 2018; 16 (21): 3164- 3165 (in Chinese).

[75] Yang XX , Cao D , Liu Q , et al. Clinical effect of Xinmailong Injection in the treatment of sepsis combined with heart failure. China Med Herald. 2019; 16 (23): 142- 145 (in Chinese).

[76] Lu CM , Yang YS , Lu YM , et al. Qishen Yiqi dripping pills for cardiovascular diseases: effects and mechanisms. Chin J Integr Med. 2023; 29 (9): 857- 864.

[77] Fu S , Zhang J , Menniti-Ippolito F , et al. Huangqi injection (a traditional Chinese patent medicine) for chronic heart failure: a systematic review. PLoS One. 2011; 6 (5): e19604.

[78] Yin HW . Study on mechanism of Yangyin Shuxin Decoction in treating heart failure with preserved ejection fraction based on metabonomics and proteomics. Tianjin University of Traditional Chinese Medicine, 2021: 1- 4 (in Chinese).

[79] Feng QT , Yang J , Zhang Y , et al. Protective effects of Buyi Qiangxin tablets on rats with chronic heart failure. Chin Tradit Pat Med. 2019; 41 (9): 2068- 2073 (in Chinese).

[80] Wan M , Yin K , Yuan J , et al. YQFM alleviated cardiac hypertrophy by apoptosis inhibition and autophagy regulation via PI3K/AKT/mTOR pathway. J Ethnopharmacol. 2022; 285: 114835.

[81] Yuan G , Liu Z , Lai Q , et al. HPLC-QTOF/MS-based metabolomics to explore the molecular mechanisms of Yiqi Fumai lyophilized injection in heart failure mice. J Separ Sci. 2021; 44 (13): 2545- 2563.

[82] Hu SY , Zhou Y , Zhong SJ , et al. Shenmai injection improves hypertensive heart failure by inhibiting myocardial fibrosis via TGF-β 1/Smad pathway regulation. Chin J Integr Med. 2023; 29 (2): 119- 126.

[83] Chen L , Zhou X , Deng Y , et al. Zhenwu decoction ameliorates cardiac hypertrophy through activating sGC (soluble guanylate cyclase)-cGMP (cyclic guanosine monophosphate)-PKG (protein kinase G) pathway. J Ethnopharmacol. 2023; 300: 115705.

[84] Che C , Wang XL , Chen ZY , et al. Effect of Zhenwu decoction on electrical remodeling of cardiomyocytes in heart failure via I_(to)/Kv channels. China J Chin Mater Med. 2023; 48 (13): 3565- 3575 (in Chinese).

[85] Fan CL , Cai WJ , Ye MN , et al. Qili Qiangxin, a compound herbal medicine formula, alleviates hypoxia-reoxygenation-induced apoptotic and autophagic cell death via suppression of ROS/AMPK/mTOR pathway in vitro. J Integr Med. 2022; 20 (4): 365- 375.

[86] Ni J , Shi Y , Li L , et al. Cardioprotection against heart failure by Shenfu injection via TGF-β/Smads signaling pathway. Evid Based Complementary Altern Med. 2017; 2017: 7083016.

[87] Jin L , Yin Q , Mao Y , et al. Putative prevention of XML injection against myocardial ischemia is mediated by PKC and PLA2 proteins. Front Cell Dev Biol. 2022; 10: 827691.

[88] Liang B , Yan C , Zhang L , et al. The effect of acupuncture and moxibustion on heart function in heart failure patients: a systematic review and meta-analysis. Evid Based Complementary Altern Med. 2019; 2019: 6074967.

[89] Roger VL . Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021; 128 (10): 1421- 1434.

[90] Wang C , Schmid CH , Rones R , et al. A randomized trial of tai chi for fibromyalgia. N Engl J Med. 2010; 363 (8): 743- 754.

[91] Hui J , Wang Y , Zhao J , Cong W , Xu F . Effects of Tai Chi on health status in adults with chronic heart failure: a systematic review and meta-analysis. Front Cardiovasc Med. 2022; 9: 953657.

[92] Taylor-Piliae R , Finley BA . Benefits of Tai Chi exercise among adults with chronic heart failure: a systematic review and meta-analysis. J Cardiovasc Nurs. 2020; 35 (5): 423- 434.

[93] Zou L , Pan Z , Yeung A , et al. A review study on the beneficial effects of Baduanjin. J Altern Complementary Med. 2018; 24 (4): 324- 335.

[94] Fang J , Zhang L , Wu F , Ye J , Cai S , Lian X . The safety of Baduanjin exercise: a systematic review. Evid Based Complementary Altern Med. 2021; 2021: 8867098.

[95] Yang WY , Xu Y , Ye L , et al. Effects of Baduanjin exercise on quality-of-life and exercise capacity in patients with heart failure: a systematic review and meta-analysis. Compl Ther Clin Pract. 2023; 50: 101675.

[96] Zhou F , Liang N , Maier M , Liu JP . Sanfu acupoint herbal patching for stable asthma: a systematic review and meta-analysis of randomised controlled trials. Compl Ther Med. 2017; 30: 40- 53.

[97] Liu N , Song XB , Tan LN , et al. Cohort study on prevention and treatment of Yang-qi deficiency and blood stasis and water stasis syndrome of chronic heart failure with Sanfu acupoint herbal patching. J Tradit Chin Med. 2020; 61 (1): 53- 57 (in Chinese).

[98] Wang A , Zhao W , Yan K , et al. Mechanisms and efficacy of traditional Chinese medicine in heart failure. Front Pharmacol. 2022; 13: 810587.

[99] Hao P , Jiang F , Cheng J , Ma L , Zhang Y , Zhao Y . Traditional Chinese medicine for cardiovascular disease. J Am Coll Cardiol. 2017; 69 (24): 2952- 2966.

[100] Xu H , Li S , Liu J , et al. Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19. Proc Natl Acad Sci USA. 2023; 120 (18): e2301775120.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Advanced Chinese Medicine published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.